1
00:00:00,480 --> 00:00:03,040
Speaker 1: But we do know and you will recall on many

2
00:00:03,080 --> 00:00:08,520
Speaker 1: occasions we have spoken to the absolutely amazing Sally Lawrence

3
00:00:08,560 --> 00:00:13,200
Speaker 1: and her family about the loss of their little girls, Skyler. Now,

4
00:00:13,240 --> 00:00:15,560
Speaker 1: she was only thirty three months old when a manager

5
00:00:15,600 --> 00:00:19,959
Speaker 1: cockle infection ended her young life. We've spoken to that

6
00:00:20,079 --> 00:00:23,640
Speaker 1: family on numerous occasions. What they have done with their

7
00:00:23,640 --> 00:00:27,120
Speaker 1: initiative share a Chino with Skyler has been nothing short

8
00:00:27,280 --> 00:00:30,720
Speaker 1: of amazing. But they have also really done quite a

9
00:00:30,720 --> 00:00:35,080
Speaker 1: bit of work to ensure well that there was research

10
00:00:35,840 --> 00:00:41,040
Speaker 1: and that there is some studies into this illness manager cockle. Now,

11
00:00:41,080 --> 00:00:44,080
Speaker 1: this manager Cockle study is currently underway. And joining me

12
00:00:44,159 --> 00:00:45,840
Speaker 1: on the line to tell us a little bit more

13
00:00:45,880 --> 00:00:52,240
Speaker 1: from the University of Adelaide Professor in vaccine ology, Helen Marshall.

14
00:00:52,360 --> 00:00:56,440
Speaker 1: Good morning to you, Helen. Let me just try that again.

15
00:00:56,480 --> 00:01:00,440
Speaker 1: Good morning again, Helen. How are you.

16
00:00:59,440 --> 00:01:02,160
Speaker 2: Very well and thanks very much for having me on today.

17
00:01:02,280 --> 00:01:04,920
Speaker 1: Yeah, thanks so much for your time, Helen. Tell us

18
00:01:04,920 --> 00:01:07,880
Speaker 1: a little bit more about this research and where it's at.

19
00:01:09,760 --> 00:01:12,640
Speaker 2: Yeah, Well, we started the study. It's called it be

20
00:01:12,760 --> 00:01:15,720
Speaker 2: part of an MP studies because you know, we're providing

21
00:01:15,760 --> 00:01:18,840
Speaker 2: a mini copp will be that scene through all fourteen

22
00:01:18,880 --> 00:01:21,319
Speaker 2: to nineteen year olds across the Northern territory. So we're

23
00:01:21,360 --> 00:01:26,160
Speaker 2: really working with MP Health, with government with a stand

24
00:01:26,240 --> 00:01:29,199
Speaker 2: with Aboriginal community control organizations to make sure that every

25
00:01:29,280 --> 00:01:32,080
Speaker 2: fourteen to nineteen year old has that accessed through the

26
00:01:32,080 --> 00:01:35,480
Speaker 2: Minida cropp will be vaccine through the study. So this

27
00:01:35,640 --> 00:01:39,320
Speaker 2: is the license recommended that scene that is already funded

28
00:01:39,400 --> 00:01:43,200
Speaker 2: by the come Wealth government for Aboriginal baby because of

29
00:01:43,240 --> 00:01:45,560
Speaker 2: their higher risk of Minida copp wi B to D.

30
00:01:46,200 --> 00:01:49,160
Speaker 2: But true the study where we're trying to acsess how

31
00:01:49,200 --> 00:01:52,520
Speaker 2: well vaccine works and detecting against the mini coppill B

32
00:01:52,560 --> 00:01:55,600
Speaker 2: to ds in this age group and also whether it

33
00:01:55,640 --> 00:01:58,720
Speaker 2: can reduce courage and also whether it's got cost protection

34
00:01:58,800 --> 00:02:02,280
Speaker 2: against gonna rear. So it's a really important study in

35
00:02:02,520 --> 00:02:05,960
Speaker 2: thinking how we can best protect our young people from

36
00:02:06,080 --> 00:02:09,080
Speaker 2: mininga coppy's these particularly.

37
00:02:08,960 --> 00:02:11,440
Speaker 1: And where are things out at the moment with the study,

38
00:02:11,520 --> 00:02:13,359
Speaker 1: how much longer is it due to go for.

39
00:02:15,400 --> 00:02:19,400
Speaker 2: We've started back in March twenty twenty one and as

40
00:02:19,400 --> 00:02:24,960
Speaker 2: you can imagine, it's been challenging with COVID of course

41
00:02:26,480 --> 00:02:31,080
Speaker 2: being obviously making everyone very busy and importantly getting vaccinated

42
00:02:31,560 --> 00:02:34,480
Speaker 2: COVID vaccine. But the recruitment to this study, of enrollment

43
00:02:34,480 --> 00:02:36,240
Speaker 2: in this study has been a bit slower than we

44
00:02:36,280 --> 00:02:38,880
Speaker 2: were expecting. So we've extended this study a bit longer,

45
00:02:39,639 --> 00:02:42,920
Speaker 2: but we'll certainly have to wind it up next year.

46
00:02:43,240 --> 00:02:46,320
Speaker 1: Okay, Helen. If there is anybody out there listening, how

47
00:02:46,360 --> 00:02:49,040
Speaker 1: can they get involved if they are keen to.

48
00:02:50,639 --> 00:02:53,120
Speaker 2: There's a number of ways, and I should say we

49
00:02:53,560 --> 00:02:56,239
Speaker 2: now have two thousand other two thousand young people involved,

50
00:02:56,240 --> 00:03:00,440
Speaker 2: which is fabulous, and we've been long in the study

51
00:03:00,480 --> 00:03:03,520
Speaker 2: out through the schools are very much light. The school

52
00:03:03,560 --> 00:03:07,800
Speaker 2: organization programs the young people like the ATV that's scene

53
00:03:08,360 --> 00:03:12,280
Speaker 2: and the serial technics booster VAC scene that young people

54
00:03:12,320 --> 00:03:16,040
Speaker 2: get through this school. So we've we've provided the vacccene

55
00:03:16,720 --> 00:03:22,000
Speaker 2: that way. But we've also they're also clinics established and

56
00:03:22,080 --> 00:03:26,079
Speaker 2: I've got a group of nurses. They're doing an amazing job.

57
00:03:26,960 --> 00:03:31,840
Speaker 2: So appointments can be made at Harry's place or at

58
00:03:31,880 --> 00:03:37,360
Speaker 2: the Palmerston clinics for anyone that wants to be all

59
00:03:37,400 --> 00:03:40,880
Speaker 2: take brantage off of the men property that scene three

60
00:03:40,920 --> 00:03:43,280
Speaker 2: through the study. The only other thing is we do

61
00:03:43,480 --> 00:03:46,920
Speaker 2: take folks Club on the first day and our and

62
00:03:47,080 --> 00:03:49,960
Speaker 2: through the different complete a good brief questionnaire, but that's

63
00:03:50,000 --> 00:03:51,800
Speaker 2: just to see where the people actually carrying the winning

64
00:03:51,840 --> 00:03:54,640
Speaker 2: the topics in their stroat, which is important for us

65
00:03:54,640 --> 00:03:58,120
Speaker 2: to understand as well. So there's the opportunities through the clinics,

66
00:03:58,120 --> 00:04:03,360
Speaker 2: there's opportunities through the oporiginal commendous controlled organizations as well.

67
00:04:04,520 --> 00:04:07,240
Speaker 2: And so yeah, we hope because the timing of the

68
00:04:07,320 --> 00:04:11,360
Speaker 2: study now is limitters be coming towards the end, we

69
00:04:11,360 --> 00:04:13,840
Speaker 2: do hope hesitate the advantage of being to check against

70
00:04:13,840 --> 00:04:18,240
Speaker 2: then copy B disease. So that's that. The Karmaston clinics

71
00:04:18,680 --> 00:04:22,880
Speaker 2: the availability Mondays and Thursdays and at Harry Say on

72
00:04:22,960 --> 00:04:27,560
Speaker 2: Wednesday afternoon. There is a website information you'd want to

73
00:04:27,600 --> 00:04:31,440
Speaker 2: know www dot be part of itt MT or in

74
00:04:31,520 --> 00:04:34,880
Speaker 2: lower case dot com do AU and that's that's where

75
00:04:34,880 --> 00:04:38,279
Speaker 2: you find more information about how you can be involved

76
00:04:38,320 --> 00:04:39,280
Speaker 2: and enroll in the studies.

77
00:04:39,680 --> 00:04:42,520
Speaker 1: Well, we really appreciate your time this morning. Helen Marshall

78
00:04:43,000 --> 00:04:47,080
Speaker 1: from the University of Adelaide, Professor in vaccine ology, thank

79
00:04:47,120 --> 00:04:49,120
Speaker 1: you very much for having a chat with us this morning.

80
00:04:50,160 --> 00:04:51,960
Speaker 2: Thank you very much for the opportunity.

81
00:04:52,320 --> 00:04:52,960
Speaker 1: Thank you